Global Terbium-155 Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Terbium-155 market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
In 2025, global production of Terbium-155 was approximately 62 grams, with an average global market price of around $42,000 per gram. That year, total global production capacity for Terbium-155 reached 110 grams, and the industry's average gross profit margin stood at 27%. Terbium-155 (Tb-155) is an artificial radioisotope of the rare-earth element terbium, characterized by an atomic number of 65 and a mass number of 155. It has a half-life of approximately 5.32 days and decays primarily via electron capture into stable gadolinium-155 (Gd-155). Its decay releases gamma rays—notably at energies of approximately 87 keV and 105 keV—that are suitable for Single-Photon Emission Computed Tomography (SPECT); it also produces Auger electrons and internal conversion electrons. Consequently, Tb-155 serves not only as a diagnostic imaging radionuclide but also holds potential for research into localized electron therapy. Its relatively long half-life allows for the monitoring of the in vivo distribution of antibodies, peptides, and other slow-clearing radiopharmaceuticals over several days. Furthermore, it can form a "theranostic pair" with the therapeutic isotope Terbium-161 (Tb-161)—sharing identical elemental chemistry—thereby minimizing discrepancies in chemical properties and pharmacokinetics between the diagnostic and therapeutic radionuclides.
The upstream segment of the Tb-155 industry chain primarily encompasses enriched Gd-155 or Gd-156 targets, low-to-medium energy cyclotrons, high-energy proton accelerators, on-line or off-line mass separation equipment, target stations, hot cells, and radiochemical separation consumables. CERN-MEDICIS obtained its first batch of Tb-155 in 2017, demonstrating that large-scale isotope separation facilities can supply high-purity, non-conventional medical radionuclides. Key upstream barriers include the cost and recovery of enriched gadolinium targets, the beam-resistance of the target layer, the control of radioactive impurities, and the capability for stable, batch-wise production. The midstream segment consists mainly of national laboratories, medical isotope centers, radiopharmacies, and radiopharmaceutical R&D institutions; these entities are responsible for separating Tb-155 from irradiated gadolinium targets, recovering the expensive enriched gadolinium target material, and converting the Tb-155 into a trivalent terbium ion solution suitable for radiolabeling. As terbium and gadolinium are both lanthanides with similar chemical properties, their separation typically requires techniques such as cation exchange, extraction chromatography, ion chromatography, or multi-column purification to yield products with high radionuclidic purity and high specific activity. Subsequently, Terbium-155 can be conjugated with peptides, small molecules, or antibodies using chelators like DOTA to produce investigational radiopharmaceuticals such as Terbium-155-DOTATOC. Key mid-stream quality control parameters include radionuclide identity, radionuclidic purity, radiochemical purity, specific activity, metal impurities, pH, sterility, endotoxin levels, and labeling stability. Studies have successfully produced high-quality Terbium-155 (at the ~200 MBq level) using cyclotrons and validated it through cellular uptake and animal SPECT/CT imaging, demonstrating that the production process has reached the level required for preclinical research. The downstream sector of the industry chain primarily comprises nuclear medicine centers, oncology hospitals, radiopharmaceutical companies, preclinical research institutions, and precision medicine laboratories. The primary application of Terbium-155 is SPECT imaging, which enables the monitoring of the long-term distribution of receptor-targeting drugs, antibodies, and peptides in tumors and normal organs, as well as facilitating patient screening, pharmacokinetic analysis, and therapeutic dosimetry assessment. Since Terbium-155 and Terbium-161 share identical elemental chemical properties, the same chelators and targeting molecules can be used to construct a true "same-element" theranostic pair (Terbium-155 for diagnosis and Terbium-161 for therapy); furthermore, the set comprising Terbium-149, Terbium-152, Terbium-155, and Terbium-161 covers alpha therapy, PET, SPECT, and beta/Auger electron therapy, respectively, representing a suite of terbium radionuclides with platform-level potential. The Auger electrons emitted by Terbium-155 also make it valuable for research into localized cell killing, although its potential development into a therapeutic product depends on the efficiency with which the radionuclide enters the cell and the cell nucleus. Currently, downstream activities remain focused primarily on animal imaging, quantitative SPECT, radiopharmaceutical paired evaluation, and production technology validation; the main constraints on large-scale clinical application are insufficient stable supply, the high cost of enriched target materials, and the fact that impurity control and GMP production systems have not yet fully matured.
Terbium-155 decays primarily through electron capture (EC), emitting moderately energetic X-rays and gamma photons (approximately 105 keV). This energy is ideal for SPECT imaging (single-photon emission computed tomography), enabling the acquisition of clear, high-resolution images. Furthermore, it emits virtually no high-energy beta particles, minimizing damage to surrounding healthy tissue.
Terbium has a significant advantage in that it is available in several other radioisotopes, including terbium-155 (α-emitter, used in therapy), terbium-155 (β-emitter, used in PET imaging), and terbium-155 (β-emitter, used in therapy). This means that the same element (terbium) can be used to label the same targeting molecule (such as an antibody or peptide), enabling seamless transition between diagnosis and therapy. For example, terbium-155 can be used for diagnostic imaging to determine lesion location and drug distribution, and then terbium-155 or terbium-155 can be used for precisely targeted therapy. This is known as "integrated diagnosis and therapy." Terbium-155, due to its excellent radionuclide properties and potential as a key component of integrated diagnosis and treatment, has become a hot topic in the research and development of new medical radioisotopes. Currently, its development focuses primarily on optimizing accelerator production technology and developing automated separation and purification processes. While facing challenges such as high costs and a fragile supply chain, with technological advancements and the growing global demand for precision medicine, terbium is expected to play a more significant role in nuclear medicine in the future.
Report Scope
This report is a detailed and comprehensive analysis for global Terbium-155 market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Terbium-155 market size and forecasts, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Terbium-155 market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Terbium-155 market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Gram), and average selling prices (US$/g), 2021-2032
Global Terbium-155 market shares of main players, shipments in revenue ($ Million), sales quantity (Gram), and ASP (US$/g), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Terbium-155
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Terbium-155 market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CERN, Paul Scherrer Institute, TRIUMF, Arronax, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Terbium-155 market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market Segmentation
Market segment by Type
Radionuclide Purity: <99%
Radionuclide Purity: ≥99%
Market segment by Product Form
Terbium-155 Radionuclide Stock Solution
Terbium-155 Labeling Intermediate
Terbium-155 Irradiation Target
Market segment by Production Route
Proton-induced Reaction on Enriched Gadolinium-155 Target
Proton-induced Reaction on Enriched Gadolinium-156 Target
Proton-induced Reaction on Natural Gadolinium Target
Deuteron-induced Reaction on Gadolinium Target
Market segment by Quality Grade
Nuclear Physics Research Grade
Medical Isotope Research Grade
Metrological Standard Grade
Market segment by Application
Diagnostic Imaging
Therapeutic Applications
Scientific Research
Major players covered
CERN
Paul Scherrer Institute
TRIUMF
Arronax
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Terbium-155 product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Terbium-155, with price, sales quantity, revenue, and global market share of Terbium-155 from 2021 to 2026.
Chapter 3, the Terbium-155 competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Terbium-155 breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Terbium-155 market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Terbium-155.
Chapter 14 and 15, to describe Terbium-155 sales channel, distributors, customers, research findings and conclusion.